Zygel
Phase 3- Indications
- Fragile X syndrome, 22q11.2 deletion syndrome
Company intelligence / Profile preview
Zynerba Pharmaceuticals
Devon, Pennsylvania, United Stateszynerba.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Zynerba’s lead asset Zygel™ has shown positive data in Phase 2 trials for both Fragile X syndrome and 22q11.2 deletion syndrome and was being evaluated in a pivotal Phase 3 trial (“RECONNECT”) for FXS at the time of acquisition by Harmony Biosciences.[1][7] The product has received orphan drug designation from the FDA and European Commission for both conditions.[4]
> “Zygel™…is currently being evaluated in a pivotal Phase 3 clinical trial for patients living with FXS…” [7]
> “Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome…” [1]
No products are yet approved or commercialized.- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Synthetic cannabinoids (specifically cannabidiol)Transdermal gel delivery
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zynerba Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zynerba Pharmaceuticals.